The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policy

The Oncotype DX Recurrence Score is a validated prognosticator in oestrogen receptor positive (ER+) breast cancer. Our retrospective analysis of a prospectively defined cohort summarises the clinical implications associated with Oncotype DX testing according to the Maccabi Healthcare Services (MHS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Siegelmann-Danieli, Nava, Silverman, Barbara, Zick, Aviad, Beit-Or, Anat, Katzir, Itzhak, Porath, Avi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869476/
https://www.ncbi.nlm.nih.gov/pubmed/24386009
http://dx.doi.org/10.3332/ecancer.2013.380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869476/
https://www.ncbi.nlm.nih.gov/pubmed/24386009
http://dx.doi.org/10.3332/ecancer.2013.380

Ejemplares similares